A Roche Project in Cooperation With the Bng (Association of German Resident Gastroenterologists) for Quality Assurance in the Dual- or Triple-therapy of Chronic Hepatitis C With Peg-(40kd)-Interferon Alfa 2a (Pegasys) at Hepatology Centers
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Peginterferon alfa-2a (Primary) ; Ribavirin (Primary) ; Hepatitis C protease inhibitors
- Indications Hepatitis C
- Focus Therapeutic Use
- Sponsors Roche
- 29 Aug 2020 Results (N=17093) of a pooled analysis of data from five consecutive registries including the German hepatitis C-registry (DHC-R) assessing the knowledge on the evolution of HCV GT 1a vs 1b for understanding HCV epidemiology, presented at The International Liver Congress 2020
- 27 Feb 2018 Status changed from recruiting to completed.
- 11 May 2015 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov record.